Filing Flows › Kyntra Bio (KYNB) › Q1 2026 › vs Q4 2025
Kyntra Bio (KYNB) Q1 2026 vs Q4 2025 (quarter over quarter)
Kyntra Bio's revenue rose $2.5M (+193%) from $1.3M in Q4 2025 to $3.7M in Q1 2026.
Kyntra Bio, Q1 2026: revenue $3.7M (+36% year over year), operating margin -369.7%, net loss $15.2M, operating cash flow −$13.9M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3.7M | $1.3M | $2.5M | +193% |
| Net loss | $15.2M | $14.2M | $978K | +7% |
| Costs & expenses | $18.9M | $15.5M | $3.4M | +22% |
| Operating costs | $17.6M | $14.8M | $2.8M | +19% |
| Interest & other, net | $1.4M | $708K | $672K | +95% |
| Cost of revenue | $4.1M | $278K | $3.8M | 15× |
| Research & development | $7.6M | $7.3M | $298K | +4% |
| SG&A | $5.9M | $7.2M | −$1.4M | -19% |
| Operating cash sources | $15.2M | $14.2M | $978K | +7% |
| Share-based compensation | $1.2M | $1.2M | −$38K | -3% |
| Working capital & other | $160K | −$5.3M | $5.5M | — |
| Cash used in operations | $13.9M | $18.3M | −$4.4M | -24% |
| Net loss absorbed | $15.2M | $14.2M | $978K | +7% |
Questions
How much did Kyntra Bio's revenue grow quarter over quarter in Q1 2026?
Kyntra Bio's revenue rose $2.5M (+193%) from $1.3M in Q4 2025 to $3.7M in Q1 2026.